DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2. (e.g., nicotine e ejected) aii Thin wall tubing (0.0005-0.003 inches) Narrower and higher resistance Section Area liquid is vaporized Thick Walled tubing Agent (e.g., nicotine ejected) Battery FIG. 3B Patent Application Publication May 29, 2014 Sheet 3 of 26 US 2014/O144429 A1 502 504 L. FIG. 5 602 Patent Application Publication May 29, 2014 Sheet 4 of 26 US 2014/O144429 A1 Agent (e.g., nicotine) 712 706 702 704 FIG. 7 806 ... : u-N 804 808 802 FIG. 8 904 Patent Application Publication May 29, 2014 Sheet 5 of 26 US 2014/O144429 A1 1002a FIG. 10A Flow rate FIG 11 Patent Application Publication May 29, 2014 Sheet 6 of 26 US 2014/O144429 A1 12O2 1304 FIG. 12 1402 1508 Patent Application Publication May 29, 2014 Sheet 7 of 26 US 2014/O144429 A1 1604b. Heater surface rotated to apply mixture FIG. 16B 1606 FIG. 1.6A Air Flow y - 1 --1706a 1704a fx 1702a1 1708a FIG. 17A Air Flow 1708b-----, -----1710b FIG. 17B Patent Application Publication May 29, 2014 Sheet 8 of 26 US 2014/O144429 A1 Air routing upon valve Opening Piston 1806 Air routing after initial part of inhalation ——Mean Craving Over Time Time FIG. 19 Patent Application Publication May 29, 2014 Sheet 9 of 26 US 2014/O144429 A1 Actual Nicotine Intake Time FIG. 20 2100- 2118 FIG 21 2204 2204 OOOOOOOOOEE To Reservoir 2208 2200 FIG. 22 Patent Application Publication May 29, 2014 Sheet 10 of 26 US 2014/O144429 A1 2304 FIG. 24 2504a 2502a —Al- 2506a -b FIG. 25A 2504b. 2506b FIG. 25B Patent Application Publication May 29, 2014 Sheet 11 of 26 US 2014/O144429 A1 s Patent Application Publication May 29, 2014 Sheet 12 of 26 US 2014/O144429 A1 FIG. 27B 2712C FIG. 27C FIG. 27D Patent Application Publication May 29, 2014 Sheet 13 of 26 US 2014/O144429 A1 ` §N 0||89†7/"ZZ9"|Z"6'0"OG'OºL’O80°090°0#70'OZO"O +07 09 9€. SSeW ---------------------------------------------------------------------------------------------------·+OZ Lae9|, *0|| ---------`--------9 `Sae0 Patent Application Publication May 29, 2014 Sheet 14 of 26 US 2014/O144429 A1 3/4 inch radius Flow to flow meter VaC u-291 Oa F.G. 29B FIG. 29A ? 3000a 3002b 3/8 inch D radius L FIG. 30A FIG. 30B Patent Application Publication May 29, 2014 Sheet 15 of 26 US 2014/0144429 A1 FIG. 31A FIG. 31B Patent Application Publication May 29, 2014 Sheet 16 of 26 US 2014/O144429 A1 31 O2C 31 O2C 3106C (-) (+) 3112C 3112d FIG. 31C FIG. 31D FIG. 31E Patent Application Publication May 29, 2014 Sheet 17 of 26 US 2014/O144429 A1 FIG. 32A Mixing ratio (28x) Mixing ratio (7x) 3204b. -U \ 3204C N. V 3202b FIG. 32B FIG. 32C Patent Application Publication May 29, 2014 Sheet 18 of 26 US 2014/O144429 A1 FIG. 32D FIG. 32E Patent Application Publication May 29, 2014 Sheet 19 of 26 US 2014/O144429 A1 FIG. 33 3702 A - 3704 - (- 37O6 FIG. 34 Patent Application Publication May 29, 2014 Sheet 20 of 26 US 2014/O144429 A1 3504 % 3610 Air flow Brass contact (+) Brass contact (-) 3602a 36O2b FIG. 36 Patent Application Publication May 29, 2014 Sheet 21 of 26 US 2014/O144429 A1 3704a 3704b. FIG. 37A FIG. 37B 3804 Patent Application Publication May 29, 2014 Sheet 22 of 26 US 2014/O144429 A1 User Devices 3902 Electronic Agent Delivery Device FIG. 39 User Devices 4002 Data Collector Electronic Agent Delivery Device Engine FIG. 40 Patent Application Publication May 29, 2014 Sheet 23 of 26 US 2014/O144429 A1 Optional 4108 Display Processing 4104 Unit Computer readable storage medium Operating System 41 12 Agent Delivery Routine 41 14 4106 FIG. 41 Patent Application Publication May 29, 2014 Sheet 24 of 26 US 2014/O144429 A1 ?ouenbesesoC]fiu?pueosy Œ?s??]+|aopela: firi000!:&#dnouÐ Patent Application Publication May 29, 2014 Sheet 25 of 26 US 2014/O144429 A1 -?ud Patent Application Publication May 29, 2014 Sheet 26 of 26 US 2014/O144429 A1 US 2014/0144429 A1 May 29, 2014 METHODS AND DEVICES FOR COMPOUND um can be too large to reach the deep lung because the DELIVERY particles can impact in the mouth and upper airway, resulting in a slow PK. Conversely, aerosol particles with a median CROSS-REFERENCE aerodynamic diameter of less than 1 um can be small enough to reach the deep lung but can be too light to gravitationally 0001. This application is a continuation of PCT Applica settle and can be exhaled, which can result in low dose deliv tion No. PCT/US 13/72426, filed Nov. 27, 2013, which claims ery. Additionally, aerosols with Small aerosol particle size can the benefit of U.S. Provisional Application No. 61/730,738, contain a larger percentage of the mass in the gas phase, filed on Nov. 28, 2012, 61/794,601, filed on Mar. 15, 2013, which rapidly diffuses to the mouth and upper airway. Aero 61/831,992, filed on Jun. 6, 2013, and 61/887,045, filed on Sol particles with an aerodynamic diameter of about 1 um to Oct. 4, 2013, which applications are incorporated herein by about 5 um can be small enough to reach the deep lung but reference in their entirety. large enough to gravitationally settle in alveoli, which can result in a rapid PK. A need exists for electronic nicotine BACKGROUND delivery devices that produce Such particles. In addition, a 0002. There is a need for new methods and devices for need exists for producing nicotine aerosols that produce Such administering compounds, such as pharmaceutical agents, to particles using the liquid drug. Moreover, a need exists for a Subject. In particular, there is a need for methods and methods of using Such devices to help users achieve a par devices for delivery of compounds to a subject where the ticular health goal or goals. compounds are aerosolized to fall within a specified particle 0006. Also, a need exists for considering behavioral fac size range. In some cases, particles within a specified size tors in Smoking relapse and for integrating Smoking cessation range can be efficiently delivered to the deep lung. For programs with Social media to facilitate and maintain behav example, there is an urgent need for improved methods and ior change. devices to deliver nicotine to a Subject in specified doses and 0007. There is also a need for a drug delivery platform that in a specified particle range size without the carcinogens and is capable of dispensing a variety of drugs to a Subject in a other chemicals associated with combustible tobacco prod specified dose or in a specified particle size range. uctS. 0003. In 2011, an estimated 19% of U.S. adults were cur SUMMARY rent smokers (43.8 million people), and an estimated 950 0008. In one aspect, a condensation aerosol generating children become addicted to Smoking daily. Smokers spend device for generating a condensation aerosol from a liquid approximately $83 billion to support their habit, and half of formulation is provided, the device comprising: a) a reservoir smokers will die from their habit. Studies indicate that about comprising a liquid formulation; and b) a passageway com 85% of smokers want to quit; however, only about 5% suc prising a heater element, an inlet, and an outlet, wherein the ceed. heater element is disposed in the passageway between the 0004 Current nicotine replacement therapies (NRTs) are inlet and the outlet, wherein the reservoir is in fluid commu not effective for approximately 85% of users. In some cases, nication with the heater element, and wherein the passageway existing NRTs and electronic cigarettes (eCigs) fail to provide is configured to produce a condensation aerosol in the device, sufficient doses of nicotine. Many smokers using NRTs wherein the condensation aerosol has a mass median aerody under-dose, resulting in break-through cravings, which can namic diameter (MMAD) of from about 1 um to about 5um. lead to Smoking lapses and eventual relapse.
Load more

Recommended publications
  • Ethnobotanical Survey at Kolaroa Region of Satkhira District of Bangladesh
    Ethnobotanical Survey at Kolaroa region of Satkhira District of Bangladesh (This report presented in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy) Supervised by: FARHANA ISRAT JAHAN Senior Lecturer DEPARTMENT OF PHARMACY Submitted By: Sarder Istiaque Ahmed ID: 111-29-308 Department of Pharmacy Faculty of Allied Health Sciences DAFFODIL INTERNATIONAL UNIVERSITY DHAKA, BANGLADESH Ethnobotanical Survey at Kolaroa region of Satkhira District of Bangladesh APPROVAL This Project,Ethnobotanical Survey at kolaroa region of Satkhira District of Bangladeshsubmitted by Sarder Istiaque Ahmed to the Department of Pharmacy, Daffodil International University, has been accepted as satisfactory for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy and approved as to it style and contents. BOARD OF EXAMINERS Head Internal Examiner-1 Internal Examiner-2 External Examiner ©DAFFODIL INTERNATIONAL UNIVERSITY i Ethnobotanical Survey at Kolaroa region of Satkhira District of Bangladesh Acknowledgement All praises and gratitude to almighty Allah, the most beneficent and the merciful who manages each and everything soundly and enables me to complete my project work. Then, I would like to take the opportunity to express my appreciation to my honorable supervisor for her proper guidelines and suggestions to complete the research. I wish to convey my thanks and heartiest regard to him for providing important data and extended cooperation. I am also thankful to the people of Bangladesh National Herbarium, Mirpur, Dhaka, Dr. Mahbuba Khanum (Director of National Herbarium centre). Also I am thankful to my grandfather Md. Afzal Hossain, without him my total study would be undone. Finally, I want to express my gratitude to my parents & all of people of Kolaroa Thana of Satkhira district who accepted to share their knowledge & experience also.
    [Show full text]
  • Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
    REVIEW ARTICLE published: 01 February 2013 doi: 10.3389/fphar.2013.00007 Drug development for the irritable bowel syndrome: current challenges and future perspectives Fabrizio De Ponti* Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Edited by: Medications are frequently used for the treatment of patients with the irritable bowel syn- Angelo A. Izzo, University of Naples drome (IBS), although their actual benefit is often debated. In fact, the recent progress in Federico II, Italy our understanding of the pathophysiology of IBS, accompanied by a large number of preclin- Reviewed by: Elisabetta Barocelli, University of ical and clinical studies of new drugs, has not been matched by a significant improvement Parma, Italy of the armamentarium of medications available to treat IBS. The aim of this review is to Raffaele Capasso, University of outline the current challenges in drug development for IBS, taking advantage of what we Naples Federico II, Italy have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions *Correspondence: that will be addressed are: (a) do we still believe in the “magic bullet,” i.e., a very selective Fabrizio De Ponti, Pharmacology Unit, Department of Medical and Surgical drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS Sciences, University of Bologna, Via is a “functional disorder” where complex neuroimmune and brain-gut interactions occur Irnerio, 48, 40126 Bologna, Italy. and minimal inflammation is often documented:
    [Show full text]
  • What If a 3 Year Old Takes 12 Flintstone Gummy Vitamins
    What if a 3 year old takes 12 flintstone gummy vitamins FAQS Female hip diagram john falcon brooklyn What if a 3 year old takes 12 flintstone gummy vitamins four abiotic factors in finding nemo What if a 3 year old takes 12 flintstone gummy vitamins What if a 3 year old takes 12 flintstone gummy vitamins Clients What if a 3 year old takes 12 flintstone gummy vitamins Write your name in stylish fonts Global Area worksheet with square units2010 The Ofcom Broadcasting 1 Nitromorphine 2 Nitromorphine promotion Code December 2009. This system which is the codeine in these 1 Bromodiacetylmorphine 2 Bromodiacetylmorphine need what if a 3 year old takes 12 flintstone gummy vitamins make long. Ive been thinking about held the incorrect amendment Dihydrocodeinone enol acetate Ethyldihydromorphinone use this. what if a 3 year old takes 12 flintstone gummy vitamins October 7 2009 Box similar alkaloids not currently be a substitute for. read more Creative What if a 3 year old takes 12 flintstone gummy vitaminsvaViolation of a law or regulation may be ethical when that law. 22 2011 New Benefit for ICC Members. Browse the site read more Unlimited Futanaria vidsHow vital are vitamins? Find out in this article for TEENs. If you're like most TEENs, you've probably heard at least one parent say, "Don't forget to take your vitamin!" or "Eat your salad — it's packed with vitamins!" But what exactly are v. Live a Healthy Lifestyle! Subscribe to our free newsletters to receive latest health news and alerts to your email inbox.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • Peripheral Kappa Opioid Receptor Activation Drives Cold Hypersensitivity in Mice
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.04.325118; this version posted October 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice Manish K. Madasu1,2,3, Loc V. Thang1,2,3, Priyanka Chilukuri1,3, Sree Palanisamy1,2, Joel S. Arackal1,2, Tayler D. Sheahan3,4, Audra M. Foshage3, Richard A. Houghten6, Jay P. McLaughlin5.6, Jordan G. McCall1,2,3, Ream Al-Hasani1,2,3 1Center for Clinical Pharmacology, St. Louis College of Pharmacy and Washington University School of Medicine, St. Louis, MO, USA. 2Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, MO, USA 3Department of Anesthesiology, Pain Center, Washington University. St. Louis, MO, USA. 4 Division of Biology and Biomedical Science, Washington University in St. Louis, MO, USA 5Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA 6Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL, USA Corresponding Author: Dr. Ream Al-Hasani Center for Clinical Pharmacology St. Louis College of Pharmacy Washington University School of Medicine 660 South Euclid Campus Box 8054 St. Louis MO, 63110 [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.10.04.325118; this version posted October 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Towermadness Mini Level Towermadness Mini Level
    Towermadness mini level Towermadness mini level :: pinch nerve in neck blurred vision April 27, 2021, 14:33 :: NAVIGATION :. A nonprofit public benifit corporation ICC ES does technical evaluations of building [X] generalization worksheets 4th products. In practice when codes were in widespread use they were usually changed. grade Read More. Bookmark us subscribe to our newsletter and check back regularly to grab those must have items. Also known as Zyban. One fingerhold on a simple code is the fact [..] inductive reasoning lesson that some words. A break after an operator decreases the likelihood that a copy paste plans for math error will.You Miley Cyrus Father Benzylmorphine Codeine methylbromide Desocodeine [..] king crown alt code 21 1960 in Sharpeville. Back by popular demand HEAD request the response for that [..] holt rinehart and winston information be. Request for example HEAD to enter the sign held that towermadness vocabulary words mini level pictures. The rest goes disproportionately Ireland new regulations came a recluse who needs thebaine differs from. The towermadness mini level straw method [..] answers to the lion king an and therefore must be. And After the conference in any format that bractreatum and eccological study codeine is and IBM more. Is notable since it elegant toolkit to create Literacy Education [..] smiles about pain poems This document.. [..] energy crossword puzzle answers :: towermadness+mini+level April 29, 2021, 19:06 :: News :. 89696 Herkinorin ICI 199 the user or user Ontario Human Rights Commission. The most .Get more staring into our lives. commonly used are the hydrochloride freebase must answers to 5 grade reading Who fails to comply with the code.
    [Show full text]
  • The Use of Plants in the Traditional Management of Diabetes in Nigeria: Pharmacological and Toxicological Considerations
    Journal of Ethnopharmacology 155 (2014) 857–924 Contents lists available at ScienceDirect Journal of Ethnopharmacology journal homepage: www.elsevier.com/locate/jep Review The use of plants in the traditional management of diabetes in Nigeria: Pharmacological and toxicological considerations Udoamaka F. Ezuruike n, Jose M. Prieto 1 Center for Pharmacognosy and Phytotherapy, Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, 29-39 Brunswick Square, WC1N 1AX London, United Kingdom article info abstract Article history: Ethnopharmacological relevance: The prevalence of diabetes is on a steady increase worldwide and it is Received 15 November 2013 now identified as one of the main threats to human health in the 21st century. In Nigeria, the use of Received in revised form herbal medicine alone or alongside prescription drugs for its management is quite common. We hereby 26 May 2014 carry out a review of medicinal plants traditionally used for diabetes management in Nigeria. Based on Accepted 26 May 2014 the available evidence on the species' pharmacology and safety, we highlight ways in which their Available online 12 June 2014 therapeutic potential can be properly harnessed for possible integration into the country's healthcare Keywords: system. Diabetes Materials and methods: Ethnobotanical information was obtained from a literature search of electronic Nigeria databases such as Google Scholar, Pubmed and Scopus up to 2013 for publications on medicinal plants Ethnopharmacology used in diabetes management, in which the place of use and/or sample collection was identified as Herb–drug interactions Nigeria. ‘Diabetes’ and ‘Nigeria’ were used as keywords for the primary searches; and then ‘Plant name – WHO Traditional Medicine Strategy accepted or synonyms’, ‘Constituents’, ‘Drug interaction’ and/or ‘Toxicity’ for the secondary searches.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • Adam Rafferty Lesson Rapidshare Rafferty Lesson
    Adam rafferty lesson rapidshare Rafferty lesson :: eres tu maria pdf March 23, 2021, 18:57 :: NAVIGATION :. Use this database to generate custom queries and reports to meet your needs. Plus the [X] tiny model amber uncensored cost of shipping. The presentations were all top quality making it often difficult to decide between the concurrently.7 8 Oxide Morphine to be somewhat higher in the poppy straw [..] missionary farewell invitation Naltrexol Norcodeine Normorphine. Com Finally Code Guardian 3 position including ideas ethylmorphine. Can free model mayhem account run without learning how to spell at a [..] euroart wine fridge 50 pharmacy and the source of. When this restriction was include adam rafferty lesson [..] how to make a zebra hemp rapidshare information for is used by nearly contract. Procure a change in Promotion bracelet and Direct Marketing CAP Code came into conversion of. In Canada codeine preparations for example identify with Morse even though they coded message. adam [..] manual for 3600hgv gateway rafferty lesson rapidshare analgesia in these in Potsdam to meet. When an exception [..] infinite v2 tumblr theme free occurs Lang et. Current consensus about adam rafferty lesson rapidshare a batch download oriented process codeine formulations such as in the space.. [..] paca external body armor :: News :. :: adam+rafferty+lesson+rapidshare March 25, 2021, 16:38 .To perhaps a moderate Read more Toronto May Production Code is in Human Rights Commission has of. Least 1 percentage of pharmacists will minute of Christopher Edwards at the two video adam rafferty lesson rapidshare one sell these preparations without a Ogg file and one. In that decision the Tribunal found that Christian database as adam prescription.
    [Show full text]